Prne
May 4th, 2009
PLAN-LES-OUATES, Switzerland - Viroblock SA announces that its antiviral products boosts the efficacy of facemasks by at least 99.0%, i.e. 100 times better and a peak performance of 1000 times, against avian influenza virus H5N1. Disposable facemasks are thus far not very effective against viruses, such as influenza, whose sizes are 0.02 to 0.3 microns.
Its patented technology (VCCD Tech) potentially inactivates all families and strains of enveloped viruses, like human, avian and swine Influenzas, SARS, AIDS, Ebola and smallpox viruses. VCCD Tech uses a mechanism of action that greatly limits the development of any viral resistance.
The test involved flowing air contaminated with the aerosolized avian Influenza H5N1 virus through a set of pre-impregnated facemasks. Airstreams that passed through facemasks (percolation) were then analyzed for the presence of residual infectious virus. Performance was compared to non-impregnated facemasks. This series of tests was performed at Retroscreen Virology Ltd, a recognized world leader in the research and testing of antiviral compounds and vaccines.
“We are very pleased by the excellent results obtained during the last 6 months. In-vivo campaigns (ferrets) have recently demonstrated the efficacy of VCCD Tech as an antiviral intranasal spray and this latest series of tests shows the stunning performance of our formulations on facemasks. Meanwhile the most recent ex-vivo screening campaigns prove its efficacy on additional viruses.
“H5N1 is just one of a number of emerging viruses such as SARS, and lately the swine flu, which represent a genuine threat across the globe. Viroblock has the technology platform to contribute to the development of new and innovative antiviral countermeasures, such as facemasks to protect not only frontline and government staff such as nurses, doctors, paramedics, firemen and police officers, but also the general public. I believe that Viroblock has all the assets to become a key player in pandemic influenza preparedness efforts,” comments CEO Thierry Pelet.
“All these results establish the broad spectrum of action of VCDD Tech against enveloped viruses and the flexibility in its deployment. Our technology is a breakthrough for inactivating enveloped viruses and their strains; I am convinced that we have not yet exploited all its potential. I am pleased to be part of an outstanding team that works tirelessly to develop and fully exploit our technology platform,” added Francois Gilardoni, member of the Board.
About Viroblock SA
Viroblock SA is a Swiss start-up founded in 2005, which has become a pioneer and world leader in the blocking virus transmission technology. Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide expert in artificial and bio-membranes, and non-phospholipid vesicles.
Its patented VCCD technology is suitable for solid supports, colloidal suspensions, emulsions, and aerosol sprays.
Additional information is available on the company’s website at www.viroblock.com
Contact: Dr. Thierry Pelet Chief Executive Officer Viroblock SA Phone: +41-22-884-8344 E-Mail: info@viroblock.com
Source: Viroblock SA
Contact: Dr. Thierry Pelet, Chief Executive Officer, Viroblock SA, Phone: +41-22-884-8344, E-Mail: info at viroblock.com
Filed under Business, Health, Health Care / Hospitals, Medical Equipment, New Products / Services, Pharmaceuticals, Surveys / Polls / Research | Tags: Plan-les-ouates, Swine flu, Switzerland, Viroblock SA | Comment Below
Related Press Releases HIV Vaccine Study First to Show Some Effectiveness in Preventing HIVSeptember 23rd, 2009 ROCKVILLE, Maryland -
A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection. According to final results released by the trial sponsor, the U.S. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotratm In RASeptember 1st, 2009 BASEL and REINACH, Switzerland -
- CAPRA-2-Data Will be Used to File for US Marketing Approval
Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM). The CAPRA-2 study (Circadian Administration of Prednisone in Rheumatoid Arthritis-2) was a 12-week, multicentre, double-blind phase III trial evaluating the safety and efficacy of Lodotra(TM) for the treatment of rheumatoid arthritis ("RA"), a chronic, progressive and disabling autoimmune disorder. Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A StrainsAugust 26th, 2009 SARASOTA, Florida -
Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies. Lakewood-Amedex's nRNA product works by selectively silencing targeted genes in the viral genome. Norovirus Aboard Cruise Ship Marco Polo Rapidly Eradicated by Revolutionary new Vaporisation ProcessAugust 18th, 2009 LONDON - The cruise ship Marco Polo, whose round-Britain cruise had to be cancelled because hundreds of passengers became ill with the vomiting bug Norovirus, has been totally disinfected by SitexOrbis' revolutionary infection control fogging service in just 5 hours at the Tilbury docks. During that time 375 rooms on 11 decks plus public spaces, lifts and communal areas were disinfected. Statement on News Reports about Ahmad Hamad Algosaibi & Brothers and Mr. Mohammed Salem al-HindiJuly 22nd, 2009 MANAMA, Bahrain -
Attention News Editors: Recent news reports on the employment and board status of Mr. Mohammed Salem al-Hindi at Ahmad Hamad Algosaibi & Brothers (AHAB) are incorrect. Global Airline Capacity for June Indicates 'A Glimmer of Economic Confidence', Reports OAGJune 11th, 2009 LONDON - Year on Year Decline Below 3% for First Time Since October 2008
This may be the 11th successive month of cutbacks in global airline schedules; however the rate of decline in seat capacity is lower than at any time since October 2008, reports OAG, (www.oagaviation.com), the world's leading aviation data business, as it releases its monthly report on trends in the supply of airline flights and seats. The world's airlines have scheduled 4% (104,216) fewer flights for June 2009 compared with the same month last year, with a 2% drop in seat capacity of 6.7 million fewer seats. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly PatientsJune 10th, 2009 SEATTLE - Neurim Pharmaceuticals (www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington. Chancellor Makes Wise Investment in Young PeopleApril 21st, 2009 LONDON - Groundwork Welcomes Budget Boost for Training
Groundwork - one of the country's leading providers of environmentally-focused employment schemes - welcomes the boost for youth training announced in the budget. Chief Executive of Groundwork, Tony Hawkhead, said:
"This is great news for the thousands of young people who were in danger of becoming a 'lost generation' with few job prospects. Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry EyeApril 14th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal SprayMarch 30th, 2009 GENEVA, Switzerland - Viroblock SA has announced today that the first generation of
VCCD Tech antiviral nasal spray formulation is active against human
influenza. Viroblock's patented Cholesterol Catalytic Depletion Technology
(VCCD Tech) inactivates enveloped viruses during the extra-cellular phase, by
altering and destabilizing cholesterol-rich viral envelopes.
Related News Crime branch in Pune seizes about 73, 000 fake swine flu facemasksSeptember 24th, 2009 PUNE - The crime branch has seized about 73,000 fake N95 facemasks from two different warehouses in Pune and arrested two people involved. he raid was conducted after specific information from N95 manufacturing Company, 3M, with its headquarters in America. Kolkata students wear anti-pollution facemasks as school uniformApril 24th, 2009 KOLKATA - Hundreds of children here are now wearing anti-pollution facemasks as a mandatory kit of their regular school uniform. The Apeejay School located on Park Street, which is one of most posh as well as polluted neighbourhoods of the City of Palaces has taken the initiative. Celebs paint their own masks to raise money for AfricaMarch 27th, 2009 LONDON - Celebrities like Lewis Hamilton, Paris Hilton, and Simon Cowell have decorated their own facemasks for an auction, aimed at raising 750,000 pounds for Africa. Around 20 big names associated with business, sports, music and Hollywood have contributed to the auction by painting their own facemasks. Now, a website that prays for those too busy to pray!March 26th, 2009 NEW YORK - Too busy to offer prayers? Well, don't fear the Lord, for He has come up with a unique idea to make you stay connected with him: InformationAgePrayer.com!
A website that charges you a monthly fee to say prayers for you has been launched. A typical charge is 4.95 dollars per month to say three prayers specified by you each day. M.K.Naryanan dismisses Santhanam's Pokhran-II 'failure' remarkSeptember 20th, 2009 NEW DELHI - National Security Adviser M. K. Narayanan on Sunday described the former DRDO scientist K Santhanam's claim on Pokhran-II nuclear tests as "unfortunate" and asserted that India has thermonuclear capabilities. Prince Charles' firm forced to change wording of 'misleading' medicines adMarch 22nd, 2009 LONDON - Prince Charles' Duchy Originals company has been ordered to amend a campaign promoting two of its herbal medicines after regulators said healing claims on the firm's website were 'misleading'. The Medicines and Healthcare products Regulatory Agency (MHRA) has upheld a complaint over the online advertising of two remedies, Duchy Herbals Echina-Relief Tincture and Duchy Herbals Hyperi-Lift Tincture. Prime Minister to inaugurate anti-corruption conference on WednesdayAugust 25th, 2009 NEW DELHI - Prime Minister Dr. Manmohan Singh will inaugurate a two-day Central Bureau of Investigation (CBI) conference on anti-corruption on Wednesday. Mayawati questions efficacy of central intelligenceAugust 17th, 2009 NEW DELHI - Uttar Pradesh Chief Minister Mayawati Monday questioned the authenticity and effectiveness of information supplied to states by central intelligence agencies, saying that it comes in the way of combating terrorism than helping. In her address to the joint meeting of chief ministers and state police chiefs here, Mayawati also questioned the effectiveness of the Sashastra Seema Bal deployed along Uttar Pradesh's 600-km border with Nepal. Injectable testosterone - way to effective male contraceptionMay 5th, 2009 WASHINGTON - Injectable testosterone could be the way to male contraception, that is effective, reversible, and minus serious short-term side-effects, according to a new study. 'For couples who can not, or prefer not to, use only female-oriented contraception, options have been limited to vasectomy, condom and withdrawal,' said Yi-Qun Gu, National Research Institute for Family Planning (NRIFP) in Beijing. Aniston helps boost dog food sales in GermanyApril 10th, 2009 LONDON - Former 'Friends' star Jennifer Aniston helped boost dog food sales when she appeared on a German TV show. Aniston appeared with actor Owen Wilson and ate some dog food on the show, reports thesun.co.uk.
|
|
